Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 6/20 | 0.39 |
| ▸ | KLK1 | P06870 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214363 | 0.87 | CYP1A2 (0.44) | BRAFMEN1GAAKMT2AGRM5 | |
| SCHEMBL13429368 | 0.82 | MEN1 (0.42) | BRAFCDK8MEN1GAAKMT2A | |
| SCHEMBL3227033 | 0.82 | MEN1 (0.40) | BRAFMEN1GAAKMT2AGRM5 | |
| SCHEMBL3221532 | 0.82 | GAA (0.41) | BRAFMEN1GAAKMT2AGRM5 | |
| SCHEMBL3219003 | 0.82 | BRAF (0.48) | BRAFMEN1GAAKMT2A | |
| SCHEMBL13429319 | 0.81 | MEN1 (0.45) | MEN1GAAKMT2AGRM5GABRA1 | |
| SCHEMBL13429262 | 0.81 | F2 (0.46) | BRAFMEN1GAAKMT2AKDR | |
| SCHEMBL3213960 | 0.80 | MEN1 (0.40) | BRAFMEN1GAAKMT2A | |
| SCHEMBL3214639 | 0.80 | SMN1; SMN2 (0.49) | BRAFMEN1GAAKMT2A | |
| SCHEMBL13429362 | 0.80 | CACNA1B (0.41) | BRAFMEN1GAAKMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | ABL1 93/4885KLKB1 4198/4885BRAF 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.